Fig. 4: Cumulative rates of deep molecular responses (MR4 or MR4.5) in evaluablea patients. | Leukemia

Fig. 4: Cumulative rates of deep molecular responses (MR4 or MR4.5) in evaluablea patients.

From: Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results

Fig. 4

MMR major molecular response, MR4, BCR::ABL1IS ≤ 0.01%; MR4.5, BCR::ABL1IS ≤ 0.0032%. aIncluded all patients with evaluable transcripts not expressing an atypical or e1a2 or unknown transcript and not having a missing evaluation at screening.

Back to article page